---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-222823"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-08-17T23:59:59+00:00"
generated_at: "2026-06-23T23:09:57.895425+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics appoints Michael Vasconcelles to board; CMO Jeffrey Humphrey departs

## Summary
- Michael Vasconcelles, M.D. appointed to board, filling vacancy from Alexis Borisy not being reelected.
- Vasconcelles brings 30+ years in oncology; served as CMO at Flatiron Health and Unum Therapeutics.
- Chief Medical Officer Jeffrey Humphrey parted ways on August 15, 2022, not due to disagreement.
- Shawn Rose, M.D., Ph.D., appointed SVP and Head of Clinical Development effective immediately.
- Rose joined Magenta in February 2022; previously at Annexon, Janssen, and Bristol Myers Squibb.

## SEC filing metadata
- accession: 0001193125-22-222823
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-08-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/0001193125-22-222823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/d390683d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-222823
- JSON: https://secwatch.observer/filing/0001193125-22-222823.json
- Plain text: https://secwatch.observer/filing/0001193125-22-222823.txt

## Key facts
- Executive change
  Michael Vasconcelles was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Director
  source text: On August 15, 2022, the Board of Directors (the “Board”) of Magenta Therapeutics, Inc. (the “Company”) unanimously appointed Michael Vasconcelles to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/0001193125-22-222823-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.